standard dose ARA-C

ApprovedSmall molecule

NNational Research Center for Hematology, Russia

standard dose ARA-C is one of 37 small molecule programs targeting Adult Acute Myeloid Leukemia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adult Acute Myeloid LeukemiaActive, not recruiting

Septic ShockActive, not recruiting

Adult Acute Myeloid LeukemiaApproved

Active, not recruiting

Septic ShockPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

224 competitors in Septic Shock

#DrugCompanyPhaseTrials

standard dose ARA-C

NNational Research Center for Hematology, Russia

Approved

1 2

Primaxin

Pfizer

Preclinical

2 3

Intropin

Pfizer

Preclinical

2 4

Zyvox

Pfizer

Preclinical

1 5

Doribax

Spravato

2 7

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 8

Cubicin

BBaxter Healthcare Corporation

Preclinical

1 9

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 10

Avastin

BBio-Thera Solutions

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Septic Shock1 trial

Russian Clinical Trial of Mesenchymal Cells in Patients With Septic Shock and Severe Neutropenia

Unknown status·NNational Research Center for Hematology, Russia·Phase 1/2·NCT01849237·30 enrolled

Adult Acute Myeloid Leukemia1 trial

3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia

Unknown status·NNational Research Center for Hematology, Russia·Phase 4·NCT01587430·245 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for standard dose ARA-C. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — standard dose ARA-C compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for standard dose ARA-C. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Research Center for Hematology, Russia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: NNational Research Center for Hematology, Russia

standard dose ARA-C

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Septic Shock1 trial

Adult Acute Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News